Decline in prostate-specific antigen (PSA) screening followed U.S. Preventive Services Task Force recommendations.
Conversations about benefits and drawbacks of PSA testing improved after the USPSTF updated its recommendations on PSA testing; however, some disparities in quality of these discussions increased.
The implementation of recommendations opposing regular prostate cancer screening appear to have lowered treatment rates dramatically.
New research results favor testing for prostate specific antigen (PSA) levels for detection of prostate cancer. PSA tests can reduce the number of fatal cases of prostate cancer by detecting disease early.
This fact sheet reviews the PSA test for prostate cancer, in particular screening recommendations, test limitations, and possible improvements the future may hold in store for the test.
The impact on PSA screening and prostate cancer incidence before and after the 2012 USPSTF screening recommendations were examined in two recent studies.
A new test is better at detecting aggressive prostate cancer than measuring PSA levels. The new test discovers aggressive cancer earlier and reduces the number of false positive tests and unnecessary biopsies.
Some patients whose PSA levels become elevated after prostatectomy may die as a result of a cause unrelated to prostate cancer.
Use of biennial strategy with longer interval for low PSA levels reduces tests, false-positive results.
Physicians' practice styles related to informed decision-making for prostate-specific antigen (PSA) screening are linked to their personal beliefs about screening.
Based on pre-PSA testing era estimates, expected cases at presentation three-fold higher than observed.
Barriers to discontinuation of screening include patient expectations, time constraints.
Extended follow-up shows reduced risk of death from prostate cancer, but not overall risk of death
A striking decline in prostate cancer mortality in the US compared with the UK from 1994 to 2004 coincided with a much higher uptake of prostate specific antigen (PSA) screening in the US.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|